Veeva: A Top 20 Customer Loss Spooks Investors, but Our Long-Term View Remains Favorable

Wide-moat Veeva shares declined 5% on Dec. 11 after a key executive member noted at an investor conference that one of Veeva’s customers chose Salesforce over Veeva during a CRM migration process. For context, Veeva has spent the last few years building out its core CRM business to migrate from the Salesforce 1 platform to the Vault platform following the decision not to renegotiate its contract with Salesforce. The migration process has been ongoing for about a year, and, so far, four of the top 20 biopharma companies have committed to transitioning to Veeva's Vault CRM. Management noted that most customers will migrate over by the end of 2026. Today’s news came as a surprise, given that we had interpreted the management’s tone regarding customer retention throughout the past year as positive and expected no major customer losses. We think investors are feeling a similar level of surprise with shares declining materially.